Low expression of Aldo–keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma by unknown
Guo et al. Cell Biosci  (2016) 6:18 
DOI 10.1186/s13578-016-0082-x
RESEARCH
Low expression of Aldo–keto reductase 
1B10 is a novel independent prognostic 
indicator for nasopharyngeal carcinoma
Yuanwei Guo1,2†, Weihao Luo1†, Zheng Hu1,4†, Jia Li1, Xiaojie Li2, Huiqiu Cao2, Jun Li3, Bo Wen1, Jian Zhang1, 
Hao Cheng3, Wangyuan Guo1, Tan Tan1,2* and Dixian Luo1,2*
Abstract 
Background: Nasopharyngeal carcinoma (NPC) is one of the most common human head and neck cancers with 
high incidence in Southern China, Southeast Asia and North Africa. Because of its nonspecific symptoms, the early 
diagnosis of NPC is very difficult. The 5-year survival rate is not ideal in spite of great innovations in radiation and 
chemotherapy treatments. Highly sensitive and specific prognostic biomarkers are eager for NPC clinical diagnosis. 
To find specific target molecules is very important for individualized treatment. Aldo–keto reductase B10 (AKR1B10) is 
closely related to tumorigenesis and tumor development, and however, its expression level in NPC tissues is not clear.
Results: AKR1B10 expression levels were validated in benign, para-cancerous nasopharyngeal and NPC tissues by 
immunohistochemical evaluation. AKR1B10 was positively expressed in 42 (82.4 %) of 51 benign specimens, and 235 
(98.7 %) of 238 para-carcinoma specimens. This percentage was significantly higher than 44.5 % (133/299) in naso-
pharyngeal carcinoma tissue (p < 0.01). AKR1B10 mRNA quantitative levels detected by real-time quantitative RT-PCR 
in 90 NPC tissue samples (0.10 ± 0.21) were significantly lower than that in 15 benign tissue samples (1.03 ± 1.12) 
(p < 0.01). AKR1B10 expression levels in NPC were correlated negatively with T-classification, lymph node metastasis 
(p < 0.05). We established nasopharyngeal cancer monoclonal cells CNE-2/AKR1B10 with AKR1B10 stable expression 
and CNE-2/vector cells without AKR1B10 expression by using a modified lentivirus-mediated method, and found that 
AKR1B10 inhibited the proliferation of CNE-2/AKR1B10 cells by using MTT assay and flow cytometry, and cell migra-
tion by in vitro scratch test.
Conclusion: Taken together, our data suggest that low expression of AKR1B10 is an independent prognostic indica-
tor in nasopharyngeal carcinoma, and that AKR1B10 may be involved in regulating the proliferation and migration of 
nasopharyngeal cancer cells.
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Background
Nasopharyngeal carcinoma (NPC) is one of the most 
common human head and neck cancers. Its development 
has been related to Epstein-Barr virus (EBV) infection, 
hereditary and environmental factors, and behavio-
ral habits. Incidence of NPC is high in Southern China, 
Southeast Asia and North Africa [1–3], and the incidence 
is constantly increasing as air pollution and food contam-
ination have been deteriorating in recent years [4]. Due 
to its nonspecific symptoms in the early stage, early diag-
nosis is very difficult, which has caused serious global 
health problems.
At present, the pathogenesis of NPC is not very clear 
[5], and the treatment options are limited in the absence 
of effective and specific therapeutic drugs. NPC is a 
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heterogeneous group of diseases, with substantial dif-
ferences in pathological types, degrees of tumor dif-
ferentiation, clinical manifestations, physical fitness, 
and sensitivity to radiation and chemotherapy in differ-
ent patients. Therefore, the outcome of the therapeutic 
interventions is not ideal, and the 5-year survival rate is 
still about 50 % in spite of great innovations in radiation 
and chemotherapy treatments [6, 7]. At present, NPC is 
mainly diagnosed by imaging exams, but the high cost 
of the tests, the inaccuracy of evaluation of treatment 
efficacy and the poor sensitivity in diagnosing metasta-
sis have limited their clinical use [8]. High expression of 
matrix metalloproteinase 1 (MMP-1) and lower expres-
sion of tissue factor pathway inhibitory factor 2 (TFPI-
2) are closely related to neck lymph node metastasis of 
NPC. For this reason, they are used as a biological indi-
cator in the assessment of NPC metastasis in advanced 
stage tumors [9, 10]. However, highly sensitive and spe-
cific prognostic biomarkers are not available for NPC 
clinical diagnosis. It is very important to screen out novel 
specific molecular indicators of NPC for early diagnosis 
and individualized treatment.
Aldo-keto reductase family 1 member B10 (AKR1B10), 
also called as aldose reductase like protein-1 (ARL-1), 
belongs to the aldehyde ketone reductase (AKRs) fam-
ily [11]. Its coding gene is in the q33 region of chromo-
some 7, encoding a protein composed of 316 amino 
acids, which was isolated from hepatocellular carcinoma 
in 1998 [12]. AKR1B10 not only regulates the balance of 
retinoic acid and lipid metabolism, but also participates 
in cell survival through cytotoxic carbonyl detoxifica-
tion. AKR1B10 is expressed at different levels in different 
human cancer cells, affecting the growth and survival of 
tumors, and its activity is closely related to tumor devel-
opment [13–15]. AKR1B10 is highly expressed in normal 
gastric intestinal epithelial tissue, whereas its expres-
sion is low or absent in other normal tissues. AKR1B10 
is highly expressed in variety of solid tumors such as 
liver cancer, non-small cell lung cancer, breast cancer, 
and pancreatic cancer [16–23]. However AKR1B10 was 
found to be expressed lowly or negatively in digestive 
tract tumors like as esophageal, gastric and colon cancer 
[24–27]. Therefore, AKR1B10 is a potential tumor bio-
marker and therapeutic target.
AKR1B10 expression in NPC is not clear. In this study, 
we identified AKR1B10 expression level in NPC, and the 
relationship between the expression level and clinico-
pathological parameters. The study results suggest that 
AKR1B10 may be a novel prognostic factor for human 
NPC.
Results
Lower expression of AKR1B10 in NPC
AKR1B10 protein levels were examined in 51 benign 
specimens, 238 para-carcinoma specimens and 299 
nasopharyngeal cancer specimens by immunochemis-
try. Yellow–brown granules corresponding to AKR1B10 
were detected mainly in the cytoplasm and occasionally 
in the nucleus. AKR1B10 expression levels were scored 
for staining intensity from 0 to 3+ (Fig. 1a-i). AKR1B10 
expression was detected in nasopharyngeal benign and 
para-cancerous tissues, adenoids, inflammatory hyper-
plasia, differentiated nasopharyngeal carcinoma, undif-
ferentiated nasopharyngeal carcinoma, and lymphatic 
metastases (Fig. 1a-ii). The immunohistochemical evalu-
ation histogram of 25 randomly selected cases showed 
that AKR1B10 protein expression levels (evaluation 
scores) in the cancerous tissue were lower than those 
in para-carcinoma tissue in 19 cases, and the expres-
sion levels were similar in between cancerous and para-
carcinoma tissues in only five cases, and the expression 
level in para-carcinoma tissue was higher than that in 
cancerous tissue in only one case (Fig.  1a-iii). The per-
centage of AKR1B10-positive specimens was 44.5  % 
(133/299) in the nasopharyngeal cancer tissue compared 
with 82.4 % (42/51) in benign specimens (p < 0.01) and 
98.7 % (235/238) in para-carcinoma specimens (p < 0.01) 
(Table 1). The evaluation scores of AKR1B10 expression 
in carcerous tissue was 1.91  ±  1.76, significantly lower 
than 5.52 ± 2.5 in benign specimens and 5.20 ± 2.89 in 
para-carinoma specimens(p < 0.01) (Fig. 1a-iv).
To investigate AKR1B10 mRNA expression in NPC, 
we extracted from total mRNA from 32 fresh NPC and 
10 benign tissue specimens, and AKR1B10 mRNA lev-
els were examined by RT-PCR. Human β-actin served as 
an internal control, the gray-scale comparison between 
AKR1B10 and β-actin was used to quantify the bands 
of RT-PCR. As shown in Fig.  1b, we observed signifi-
cantly lower AKR1B10 mRNA levels in NPC tissues 
(0.11  ±  0.02) than that in benign tissues(0.34  ±  0.08) 
(p  <  0.01). To further investigate quantitative expres-
sion levels of AKR1B10 mRNA in NPC, we collected 90 
NPC specimens and 15 benign specimens, which were 
subjected to ARK1B10 mRNA quantitative detection 
by using real-time qRT-PCR. Human GAPDH served 
as an internal control, and data were analyzed using the 
2∆CT method, where ∆CT  =  CtAKR1B10  −  CtGAPDH. We 
observed that AKR1B10 mRNA quantitative levels were 
lower in NPC (0.10  ±  0.21) than that in benign speci-
mens (1.03 ± 1.12) (p < 0.01), which was consist with the 
RT-PCR results.
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Fig. 1 AKR1B10 expression in NPC tissues. a AKR1B10 protein expression was detected in 299 NPC specimens, 238 para-carcinoma specimens and 
51 benign specimens by immunochemistry. i Immunohistochemical AKR1B10 staining was evaluated by scoring the staining intensity from 0 to 3+ 
: 0 for no staining (A), 1+ for weak immunoreactivity (B), 2+ for moderate immunoreactivity (C), 3+ for strong immunoreactivity (D). ii According 
to the standard, AKR1B10 expression was evaluated in: E inflammatory hyperplasia; F adenoid hypertrophy; G para-carcinoma; H undifferentiated 
nasopharyngeal carcinoma; I differentiated nasopharyngeal carcinoma; J mandibular lymphatic metastasis. iii AKR1B10 protein levels (immunohis-
tochemical staining scoring) were analyzed in 25 randomly selected paired cases of NPC and para-carcinoma. iv AKR1B10 expression levels relative 
to β-actin were compared in 51 benign, 238 para-carcinoma and 299 NPC tissue specimens (**p < 0.01). b i AKR1B10 mRNA expression detected by 
RT-PCR in some representative specimens was shown. B, Benign and T, Tumor. ii AKR1B10 mRNA levels relative to β-actin examined by RT-PCR were 
compared in 32 NPC and 10 benign tissue specimens (**p < 0.01). iii AKR1B10 mRNA levels relative to GAPDH examined by qRT-PCR were compared 
in 90 NPC and 15 benign tissue specimens (**p < 0.01)
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Correlationship between AKR1B10 expression 
and clinicopathological features in NPC
200 NPC tissue specimens with detailed clinical medi-
cal records were subjected to detecting AKR1B10 
protein expression levels by immunochemistry, and 
AKR1B10 were highly expressed in 15 cases (evalua-
tion score of AKR1B10 expression  =  3), moderately 
expressed in 33 cases (score  =  2), weakly expressed in 
73 cases (score  =  1), and negatively expressed in 79 
cases (score =  0). We statistically analyzed correlation-
ship between AKR1B10 expression levels evaluated by 
immunochemistry methods and clinicopathological fea-
tures, such as patient age, tumor type (differentiation), 
neck masses, tumor size (T classification), node metas-
tasis (N classification), distant metastasis, TNM clinical 
stage (Table 2). The frequency of AKR1B10 positivity was 
significantly higher in patients with differentiated NPC 
than that in patients with undifferentiated NPC (71.2 %, 
89/125 vs 42.7 % 32/75, p < 0.01). Furthermore, AKR1B10 
expression levels in NPC were negatively correlated 
with tumor size (r = −0.399, p < 0.001) and lymph node 
metastasis (r = −0.326, p < 0.001).
Effect of AKR1B10 on the proliferation of NPC cells
Given the negative correlation of AKR1B10 expression 
levels with tumor size, we hypothesized that AKR1B10 
could influence cell proliferation of NPC cells. To iden-
tify this hypothesis, we established CNE-2/AKR1B10 
monoclonal cells with AKR1B10 stable expression, 
and CNE-2/vector cells without AKR1B10 expres-
sion by using a modified lentivirus-mediated method, 
and examined over-expression of AKR1B10 in CNE-2/
AKR1B10 cells and negative expression of AKR1B10 in 
CNE-2/vector cells by western blot (Fig. 2a). The prolif-
eration of CNE-2/vector cells and CNE-2/AKR1B10 cells 
were measured by MTT assay and flow cytometry. As 
shown in Fig. 2b, the viability rate of 5 × 103 or 7 × 103 
CNE-2/AKR1B10 cells assayed by MTT experiments 
were respectively 62.84  ±  6.50 and 68.37  ±  10.73  %, 
related to that of CNE-2/vector cells (p < 0.05). The pro-
liferation index (PI) was significantly lower in CNE-2/
AKR1B10 (25.37  ±  5.18  %) than that in CNE-2/vector 
cells (41.56 ± 3.67 %) (p < 0.05), as shown in Fig. 2c.
Effect of AKR1B10 on the migration of NPC cells
According to the negative correlation of AKR1B10 
expression levels and tumor node metastasis, we thought 
that AKR1B10 could have influenced cell migration of 
NPC cells. The migration experiments of CNE-2/vector 
cells and CNE-2/AKR1B10 cells were done by in  vitro 
scratch assay. As shown in Fig.  3a and 3b, the scratch 
area was measured by Image-pro plus, and the migration 
rates (MR) were calculated according to the equation: 
MR % = [(Area at T0 − Area at Tt)/Area at T0] × 100 %, 
where Tt is the number of hours post-injury and T0 is the 
time of injury. As shown in Fig. 3, the migration rates of 
CNE-2/AKR1B10 cells at 24 h or 48 h were respectively 
42.62  ±  13.99 and 51.7  ±  15.12  %, relative to that of 
CNE-2/vector.
Discussion
NPC is a heterogeneous group of diseases character-
ized by different biological behaviors. To better man-
age patients with NPC, novel tumor-specific markers 
are required for diagnosis, targeted therapy, and prog-
nosis prediction. In this study, we report that AKR1B10 
expression is down-regulated in NPC, and AKR1B10 may 
represent a new clinicopathological biomarker and prog-
nostic factor for this disease.
AKR1B10 has been reported to be overexpressed in 
many non-digestive tract solid tumors such as non-
small cell lung cancer in smokers, breast cancer, pan-
creatic cancer and hepatocellular carcinoma [16, 18, 
21, 28–30]. Recent clinicopathological studies demon-
state that AKR1B10 may be a valuable biomarker of dif-
ferentiation and proliferation in liver tumors, and may 
also play a role in early phases of hepatocarcinogenesis 
[28, 31]. However, AKR1B10 expression is downregu-
lated in gastrointestinal cancers. It is very interesting 
that AKR1B10 expression shows an opposite pattern 
in digestive tract cancers compared with cancers aris-
ing outside of the digestive tracts. In the present study, 
we have found that both AKR1B10 protein and mRNA 
levels were reduced in most of NPC tumors compared 
with para-carcinoma and benign tissues, which further 
suggests that AKR1B10 expression is down-regulated 
in the digestive tract cancers. He et al. [32] also investi-
gated that AKR1B10 expression levels in NPC tissues are 
lower than that in benign tissues, which is consistent to 
our results. However, in their studies, AKR1B10 expres-
sion levels are higher in NPC tissues than that in normal 
nasopharyngeal tissues of healthy people [32], which was 
not observed in our studies because it was too difficult 
to obtain normal nasopharyngeal tissues from healthy 
Table 1 Expression of AKR1B10 in benign, para-carcinoma 
and cancer tissues





Benign 42 (82.4) 9 (17.6) 51
Para-carci-
noma
235 (98.7) 3 (1.3) 238
NPC 133 (44.5) 166 (55.5) 299 227.507 <0.001
Total 410 (69.7) 178 (30.3) 588
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persons. Therefore, we only compare AKR1B10 expres-
sion in NPC tissues with that in para-carcinoma tissues 
in same NPC patients or with that in benign tissues in 
other patients.
These digestive tract organs are directly exposed to 
luminal carbonyl toxins from the food, water and air or 
from local production by the microbiome [33]. Cao et al. 
[34] published that AKR1B10 is an important protec-
tor in the gastrointestinal epithelium. AKR1B10 plays 
important roles in detoxification of cytotoxic carbonyl 
compounds, and reduction of various aliphatic and aro-
matic α, β-unsaturated aldeketones to the respective 
alcohols [35]. The carbonyls were also produced during 
cell metabolism via the lipid peroxidation, which induces 
protein dysfunction, DNA damage and oncogenesis [35, 
36]. By efficiently detoxifying cellular carbonyls and their 
glutathione conjugates by reduction of reactive carbonyl 
groups into less active hydroxyls, AKR1B10 may protect 
host cells from carbonyl-induced lesions [34–37]. It was 
reported that N,N′-Dinitrosopiperazine (DNP), as sub-
strates of AKR1B10 enzyme, increased the expression of 
AKR1B10 in nasopharyngeal carcinoma 6-10B cells [38]. 
Though AKR1B10 is not only predominantly expressed 
in the distal gastrointestinal tract, but also in proximal 
nasopharynx, some nasopharyngeal cells with low or 
negative expression of AKR1B10 in some NPC patients 
might undergo carcinogenesis and eventually grow into 
tumors due to loss of efficient detoxification of AKR1B10, 
or excessive cytotoxic carbonyls.
Recent clinicopathological studies demonstrate that 
AKR1B10 expression in hepatocellular carcinomas differs 
depending on the disease stage. AKR1B10 is significantly 
overexpressed in lower tumor stages with underlying cir-
rhosis or viral hepatitis, whereas it is down-regulated in 
advanced tumor stages [28]. Therefore, AKR1B10 may 
be a valuable biomarker in many tumors. Our results 
showed that AKR1B10 expression levels are negatively 
correlated with tumor types, neck masses, and lymph 
node metastasis of NPC, and positively correlated with 
NPC differentiation. The positive correlation was also 
observed in Dr. He’s study [32]. However, the negative 
correlations in NPC are unlike in solid cancers outside 
of the digestive tract system. The cell proliferation and 
migration assays further confirmed the negative cor-
relation, showing that AKR1B10 inhibits cell prolifera-
tion and migration of NPC. However, In non-digestive 
Table 2 Correlation between AKR1B10 expression levels and the clinicopathologic characteristics of NPC patients
Variables AKR1B10 expression levels Sub-total Fisher’s exact tests Correlation analysis
3 2 1 0 Values p values r values p values
Subtotal 15 33 73 79 200
Age (years)
 ≤45 9 10 31 29 79 4.235 0.239 0.046 0.519
 >45 6 23 42 50 121
Tumor type
 Undifferentiation 6 10 16 43 75 18.008 <0.001 0.212 0.003
 Differentiation 9 23 57 36 125
Neck masses (cm)
 0 8 15 26 33 82 2.765 0.848 0.047 0.510
 >0, ≤3 4 10 15 13 42
 >3 3 8 32 33 76
T-classification
 T1/T2 10 21 33 18 82 36.119 <0.001 -0.399 <0.001
 T3/T4 5 12 40 61 118
N classification
 N0/N1 12 23 37 26 98 19.746 <0.001 -0.311 <0.001
 N2/N3 3 10 36 53 102
Distant metastasis
 Yes 6 6 5 18 35 12.776 0.004 0.011 0.892
 No 9 27 68 61 165
TNM clinical stage
 I–II 12 30 67 66 175 3.569 0.302 0.059 0.420
 III–IV 3 3 6 13 25
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Fig. 2 Effect of AKR1B10 on the proliferation of NPC cells. a AKR1B10 protein expression was assayed in CNE-2/AKR1B10 and CNE-2/vector cells 
by western blot. b 5 × 103 or 7 × 103 CNE-2/vector and CNE-2/AKR1B10 cells per well were seeded into 96-well plates and cultured for 72 h. Cell 
proliferation was analyzed by MTT assay (*p < 0.05). c Cell cycle distribution was detected by propidium iodide staining and flow cytometry. i Repre-
sentative cell cycle flow cytometry images of CNE-2/vector and CNE-2/AKR1B10 cells. ii Cell proliferation index (PI) was calculated according to the 
equation: PI = (S % + G2/M %)/(G0/G1 % + S % + G2/M %) × 100 %, and the PI of CNE-2/vector cells was higher than that of CNE-2/AKR1B10 cells 
(*p < 0.05). All the experiments were repeated three times at least
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tract solid tumors such as lung cancer, breast cancer, and 
hepatocellular carcinoma, AKR1B10 are over-expressed 
and stimulates cell proliferation and migration by pro-
moting lipid synthesis, activating the signaling molecule 
retinoic acid and transcription factor Nfr-2 that regulate 
cell proliferation and differentiation [39]. However, the 
mechanism on AKR1B10 suppressing cell proliferation 
and migration is not clear, which we are studying.
Therefore, we conclude that AKR1B10 may be used 
as a prognostic marker for nasopharyngeal carcinoma. 
The cause of opposite pattern of expression in cancers 
inside or outside the digestive tracts might be related to 
unknown functions of AKR1B10 in different tissues. In 
summary, AKR1B10 is negatively correlated with differ-
entiation, tumor growth and lymph node metastasis by 
inhibiting cell proliferation and migration of NPC, and 
therefore, AKR1B10 may be a valuable clinicopathologi-
cal and prognostic indicator in patients with NPC.
Conclusion
Our data demonstrates that AKR1B10 may be involved 
in regulating the proliferation and migration of 
nasopharyngeal cancer cells, and AKR1B10 expression 
levels are negative correlated with lymph node metastasis 
of nasopharyngeal carcinoma. Therefore low expression 




With an IRB protocol (ky2013005) approved by Ethics 
Committee of the First People’s Hospital of Chenzhou, 
we procured paraffin-embedded formalin-fixed speci-
mens including benign specimens (n = 51), nasopharyn-
geal cancer specimens (n  =  299) and para-carcinoma 
specimens (n = 238) collected and identified were identi-
fied from the archives of Department of Pathology in the 
First People’s Hospital of Chenzhou between 2008 and 
2015. The samples were used to detect AKR1B10 expres-
sion by immunochemical assay. Freshly frozen tumor tis-
sues (n = 90) and benign tissues (n = 15) were obtained 
from Department of E.M.T. in the First People’s Hospi-
tal of Chenzhou, and were used for AKR1B10 mRNA 
analysis by RT-PCR and qRT-PCR. All the samples with 
Fig. 3 Effect of AKR1B10 on the migration of NPC cells. a In vitro scratch assay. The same numbers of CNE-2/vector and CNE-2/AKR1B10 cells were 
cultured in 6-well plates. The bottoms of the plates were scratched when the cells were cultured to confluency. The images were captured at 0, 24 
and 48 h. b Histogram of cell migration ratio (MR) calculated by using the equation: MR % = [(Area at T0 − Area at Tt)/Area at T0] × 100 % (t = 24 h 
or t = 48 h). The experiments were repeated three times at least (*p < 0.05)
Page 8 of 10Guo et al. Cell Biosci  (2016) 6:18 
pathological diagnosis were confirmed by the professors 
in Chenzhou Pathology Center in the First People’s Hos-
pital of Chenzhou.
Immunohistochemistry method
For immunohistochemical analysis, paraffin-embedded 
tissue sections were deparaffinized in xylene, washed 
with ethanol, rehydrated, and then incubated with fresh 
3  % (v/v) H2O2 for 10  min for eliminating endogenous 
peroxidase activity. After being rinsed with distilled 
water, sections were washed three times with phosphate-
buffered saline (PBS) for 5 min each time, and then incu-
bated with 10 % (v/v) normal goat serum (diluted in PBS) 
at room temperature for 20 min. The sections were then 
incubated with rabbit anti-AKR1B10 antibodies for 1.5 h 
at 37  °C, followed by incubation with HRP-labeled sec-
ondary antibody at 37  °C for 30  min. Subsequently, the 
sections were stained with 3,3-diaminobenzidine (DAB) 
for 5–10 min and counterstained with hematoxylin.
All slides were observed under a Leica light microscope 
DM4 B (Leica Corporation, Germany) at high magnifica-
tion and five microscopic fields were randomly selected 
for immunochemical evaluation. AKR1B10 expres-
sion levels were scored on staining intensities from 0 to 
3+ (0 for no staining, 1+ for weak immunoreactivity, 
2+ for moderate immunoreactivity and 3+ for strong 
immunoreactivity). The percentage of cells with positive 
AKR1B10 staining within the cancerous region of a sec-
tion were scored as follows: 0 for <5 % positive cells, 1+ 
for 5‒10  %, 2+ for 11–50  % and 3+ for 51‒100  %. The 
percentages within para-cancerous region of the same 
section were scored according to the same evaluation 
standard. The intensity and proportion scores were then 
multiplied to obtain a composite score. The values of the 
composite score ranged between 0 and 9, and we defined 
a score of <2 as negative, of 2‒3 as weakly positive, of 4‒5 
as moderately positive, and of ≥6 as strongly positive.
RNA preparation, RT-PCR and real-time fluorescence 
quantative RT-PCR (qRT-PCR)
Total RNA was extracted using Trizol® reagent (Invitro-
gen, CA) and quantitated at OD260 with a multiscan spec-
trometer (Thermo Varioskan Flash, Wilmington, DE). 
The RNA integrity was verified by gel electrophoresis. 
RNA was treated with RNase-free DNase 1, and the first-
strand cDNA was synthesized from 1  µg of total RNA 
with oligo-dT primers and GoSript® retrotranscriptase, 
following the manufacturer’s protocol (Promega, USA). 
The PCR reactions were performed as follows: initial 
denaturation at 94  °C for 5 min, implification (94  °C for 
30  s, 58  °C for 45  s, 72  °C for 30  s, and 32 cycles), and 
final extension at 72  °C for 10  min. β-actin mRNA in 
each sample was run in parallel for an internal control. 
Primers for AKR1B10 are 5′-CTG GAT CCG GCA AGA 
TTA AGG AGA T (forward) and 5′-GAC TGC GGC 
CGC GAT ATC CAC CAG G (reverse), and primers for 
β-actin are 5′-ATC ATT GCT CCT CCT GAG CGC 
(forward) and 5′-TGA ACT TTG GGG GAT GCT CGC 
(reverse). The PCR products were run in agarose-gel, and 
the gray values of AKR1B10 and β-actin were scanned by 
Alpha View SA 3.30 (Cell Biosciences, USA) and semi-
quantitative expression level of AKR1B10 was calculated 
relative to β-actin.
QPCR reactions were performed using SYBR Premix 
Ex Roche (Roche SYBR Green I, Swit.) in a total vol-
ume of 20 μl containing 1 µl of cDNA, 0.5 µl of forward 
and 0.5 µl of reverse primers. The qPCR reactions were 
performed as follows: initial denaturation at 95  °C for 
10 min, amplification (95 °C for 30 s, 55 °C for 30 s, 72 °C 
for 30 s, 33 cycles). QPCR with GAPDH-specific primers 
was run in parallel in each sample as an internal control. 
The primers for AKR1B10 were 5′-CAG AAG ACC CTT 
CCC TGC TG (forward) and 5′-CGT TAC AGG CCC 
TCC AGT TT (reverse), and for GAPDH were 5′-GAA 
GGT GAA GGT CGG AGT CA (forward) and 5′-GGA 
AGA TGG TGA TGG GAT TTC (reverse). The relative 
amount of AKR1B10 mRNA to GAPDH was calculated 
as 2∆CT, where ∆CT = CtAKR1B10 − CtGAPDH.
Cell culture and stable clone establishment
Human nasopharyngeal carcinoma (hNPC) CNE-2 cells 
were obtained from the Xiangya Hospital, Changsha, 
China, were grown in RPMI-1640 medium (Hyclone, 
UT) supplemented with 10 % fetal bovine serum (Gibco/
BRL, Grand Island, NY) and 100  U/ml penicillin and 
100  mg/ml streptomycin at 37  °C in a 5  % CO2 atmos-
phere. To overexpress AKR1B10 in CNE-2 cells, we 
cloned AKR1B10 gene into a modified lentivirus vector 
in which AKR1B10 was co-expressed with puromycine-
resistant gene (pSIN-EF2-AKR1B10-Puromycin). The 
lentivirus vector pSIN-EF2-AKR1B10-Puromycin or 
control empty lentivirus vector pSIN-EF2-Puromycin 
together with auxiliary plasmids pSPAX2 and pMD2.G 
were transfected into 293T cells to package lentivirus. 
After infected by lentivirus, CNE-2/AKR1B10 cell clones 
and the control CNE-2/vector cells were screened out 
through adding puromycin into the mediums. The stable 
expression of AKR1B10 was detected using western blot 
method. CNE-2/AKR1B10 and CNE-2/vector cells were 
used in the following experiments.
Protein extraction and western blot
Total cellular proteins were extracted always on ice using 
Roche lysate buffer (Roche, Switzerland). Protein con-
centration was quantitated with BCA method. 45  μg of 
total protein extracts were loaded in 12  % SDS-PAGE 
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gel, electrophoresed at 80–120  V at room temperature, 
then transferred to a nitrocellulose membrane (Milli-
pore, Bedford, MA) at 200 mA for 90 min at 4 °C. After 
blocked with 5 % milk in PBST buffer for 45 min at the 
room temperature, the membrane was incubated with 
self-prepared rabbit anti-AKR1B10 primary antibody 
(1:500) and mouse anti-β-actin antibody (1:5000) (Sigma-
Aldrich Company, USA) for 8 h at 4°, and then incubated 
with secondary antibodies tagged with chemolumines-
cence for 1  h at room temperature. Finally the protein 
expression levels in the membrane were detected by Tita-
tive Analysis System (Alpha Fluor chem Q, protein sim-
ple, USA).
MTT assay
CNE-2/vector and CNE-2/AKR1B10 cells (5  ×  103 or 
7  ×  103 per well) were seeded into 96-well plates and 
cultured for 72  h. 20  µl of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) were added 
into each well. The cells were incubated at 37  °C for 
4 h. Subsequently, the supernatant in each well was dis-
carded, and 150 µl of dimethylsulfoxide were then added 
into each well. The plates were shaken for 10 min to make 
the crystals fully dissolved. Finally, the OD value was 
measured at 490  nm with the multiscan spectrometer 
(Thermo Varioskan Flash, Wilmington, DE) and the per-
centage of viable cells of CNE-2/AKR1B10 normalized to 
CNE-2/vector was calculated.
Cell cycle assay
CNE-2/vector and CNE-2/AKR1B10 cells (1 ×  106 in a 
60  mm-diameter dish) were incubated in medium with 
10 % FBS for 24 h. After collected and fixed in 750 µl ice-
cold alcohol for 2 h at 4 °C. The fixed cells were collected 
by centrifuging at 1000g for 5 min. washing with 1 ml ice-
cold PBS and then resuspended in 250  µl ice-cold PBS, 
incubated in PBS containing 10  µl RNase A for 30  min 
at 37 °C. Finally, 12 µl of propidium iodide (PI) solution 
were added to each tube for 30 min on ice. The samples 
were immediately examined with red fluorescence at a 
wavelength of 488  nm by using a FACstar Plus cytom-
eter (Beckman Germany). Light scattering was detected 
at the same time. The cellular DNA content and light 
scattering were analyzed by Cell Quest software (Bec-
ton–Dickinson, USA). PIs [(cell number in S  +  G2/M 
phages)/(total cell number)] were calculated to identify 
cell proliferation.
Scratch assay
The same number of CNE-2/vector and CNE-2/
AKR1B10 cells was cultured in a 24-well plate. When 
the cells were cultured to confluency, they were then 
scratched with a 200 μl pipette tip and further incubated 
in DMEM supplemented with 1  % FBS. Images were 
taken at 24, and 48 h with a Leica light microscope DM4 
B (Leica Corporation, Germany). The Image-Pro plus 
image analysis system was used to measure the lesion 
area. The data were expressed as cell migration ratio 
(MR %) using the equation: MR % = [(Area at T0 − Area 
at Tt)/Area at T0,] ×  100  %, where Tt is the number of 
hours post-injury and T0 is the time of injury.
Statistical analysis
Statistical analysis was performed using the Statistical 
Package for Social Sciences (SPSS) for Windows, version 
18.0 (SPSS, Chicago, IL, USA). All data were described 
as mean ± SD. Fisher’s exact test and Spearman correla-
tion analysis were produced to examine the relationship 
between AKR1B10 expression and clinicopathological 
variables. T test was used to analyze cell proliferation and 
cell migration. Results were considered statistically sig-
nificant for p < 0.05.
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